Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Using HIV viral load to guide treatment-for-prevention interventions.

Novitsky V, Essex M.

Curr Opin HIV AIDS. 2012 Mar;7(2):117-24. doi: 10.1097/COH.0b013e32834fe8ff. Review.

PMID:
22258501
2.

Preventing HIV transmission through antiretroviral treatment-mediated virologic suppression: aspects of an emerging scientific agenda.

Dieffenbach CW.

Curr Opin HIV AIDS. 2012 Mar;7(2):106-10. doi: 10.1097/COH.0b013e32834f3f13. Review.

PMID:
22227584
3.
4.

Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.

Gianella S, von Wyl V, Fischer M, Niederoest B, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2011;16(4):535-45. doi: 10.3851/IMP1776.

PMID:
21685541
5.

Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052.

Forsyth AD, Valdiserri RO.

Curr Opin HIV AIDS. 2012 Mar;7(2):111-6. doi: 10.1097/COH.0b013e32834fcff6. Review.

PMID:
22227586
6.

[Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].

Marcello A, Giacca M.

Pathologica. 2000 Aug;92(4):291-3. Italian. No abstract available.

PMID:
11029891
7.

HIV-1 DNA and RNA kinetics in primary HIV infection.

Lillo F, Grasso M, Lodini S, Capiluppi B, Lazzarin A, Tambussi G.

J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):49-52.

PMID:
12003174
8.

Treatment-for-prevention: clinical considerations.

Lockman S, Sax P.

Curr Opin HIV AIDS. 2012 Mar;7(2):131-9. doi: 10.1097/COH.0b013e32834fcf6b. Review.

PMID:
22227588
9.

Benefits from early treatment of HIV-1 infection.

Klein D.

Trends Mol Med. 2001 Jan;7(1):9. No abstract available.

PMID:
11427995
10.

Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.

Celum CL, Buchbinder SP, Donnell D, Douglas JM Jr, Mayer K, Koblin B, Marmor M, Bozeman S, Grant RM, Flores J, Sheppard HW.

J Infect Dis. 2001 Jan 1;183(1):23-35. Epub 2000 Dec 8.

PMID:
11106536
11.

Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy.

Trøseid M, Nowak P, Nyström J, Lindkvist A, Abdurahman S, Sönnerborg A.

AIDS. 2010 Jul 17;24(11):1733-7. doi: 10.1097/QAD.0b013e32833b254d.

PMID:
20502315
12.

Can HIV infection be eradicated through use of potent antiviral agents?

Josefsson L, Dahl V, Palmer S.

Curr Opin Infect Dis. 2010 Dec;23(6):628-32. doi: 10.1097/QCO.0b013e32833ff1d0. Review.

PMID:
20847693
13.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
14.

[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

Panel de expertos de GESIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Spanish.

PMID:
21388714
15.

Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.

Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.

J Med Virol. 2004 Jul;73(3):350-61.

PMID:
15170628
16.

Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.

Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Pisapia M, Delbeke E.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):44-55.

PMID:
11176268
17.
18.

Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert.

Kim HN, Tabet SR, Corey L, Celum CL.

Vaccine. 2006 Jan 23;24(4):532-9. Epub 2005 Oct 5.

PMID:
16242816
19.

How reliable is an undetectable viral load?

Combescure C, Vallier N, Ledergerber B, Cavassini M, Furrer H, Rauch A, Battegay M, Bernasconi E, Vernazza P, Hirschel B; Swiss HIV Cohort Study.

HIV Med. 2009 Sep;10(8):470-6. doi: 10.1111/j.1468-1293.2009.00714.x. Epub 2009 May 6.

20.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573

Supplemental Content

Support Center